在宫癌衍生的细胞系中,甲福明通过mTORC1抑制诱导ZFP36
Karen Griselda De la Cruz-López1,2, Eduardo Alvarado-Ortiz3, Heriberto A Valencia-González4
1Programa de Doctorado en Ciencias Biomédicas, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Mexico City, Mexico.
BMC cancer
|July 18, 2024
概括
甲福明是一种抗糖尿病药物,通过调节基因表达来表现出抗癌效应. 这项研究确定了ZFP36作为一个关键标,通过mTORC1抑制被甲福林激活,这表明了癌症的新治疗策略.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 甲胺是一种常见的抗糖尿病药物,具有抗癌性质.
- 它的作用部分由AMPK-mTORC1通路介导,但正在出现替代机制.
- 了解这些途径对于新的癌症疗法至关重要.
研究的目的:
- 为了研究甲胺的分子标和癌症中的基因表达变化.
- 探索ZFP36在甲胺抗癌作用中的作用.
- 阐明涉及美特福林作用的特定信号通路.
主要方法:
- 在用甲胺治疗的老鼠异种移植模型中进行转录组查.
- 验证使用西布洛特,免疫组织化学和RT-qPCR.
- 在宫癌患者基因表达的基因分析和涉及AMPK淘汰和mTOR抑制的机制研究.
主要成果:
- 甲胺降低了瘤生长,并提高了抗瘤基因的调节.
- ZFP36被确定为一种新的甲胺诱导的标.
- 甲胺诱导ZFP36依赖于mTORC1抑制,但在HeLa细胞中不依赖AMPK.
结论:
- 甲胺的抗癌作用涉及到ZFP36的激活.
- mTORC1抑制是甲胺诱导的ZFP36表达的一个关键机制.
- 进一步研究调节mTORC1的替代途径是有必要的.
相关概念视频
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K


